Precision medicine approach for leukemia treatment
The Patient Cohort of the National Center for Precision Medicine in Leukemia
This study is trying to find better ways to treat people with newly diagnosed leukemia by collecting data to create personalized treatment plans.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Drugs / interventions | ruxolitinib, chemotherapy |
| Locations | 3 sites (Bobigny and 2 other locations) |
| Trial ID | NCT05326919 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with newly diagnosed leukemia and related disorders, aiming to gather data for precision medicine approaches in treatment. Conducted by the French National Center for Precision Medicine in Leukemia, the study involves biobanking to support future therapeutic strategies tailored to specific patient subsets. By analyzing patient data in a real-life environment, the study seeks to enhance understanding and treatment of various leukemia types. It is part of a broader initiative to improve care and research in leukemia.
Who should consider this trial
Good fit: Ideal candidates include patients with newly diagnosed, previously untreated acute myeloid leukemia, acute lymphoblastic leukemia, or related disorders.
Not a fit: Patients with previously treated leukemia or those with unproven morphological diagnosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment options for patients with leukemia.
How similar studies have performed: Other studies in precision medicine for leukemia have shown promise, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient with newly diagnosed previously untreated de novo, secondary or therapy-related leukemia or related disorders (LRD), including AML, ALL, HR-MDS (according to the international score IPSS), and MNP-related myelofibrosis * Patient informed and not opposed to participating * Affiliation to social security or any health insurance Exclusion Criteria: * LRD which is not morphologically proven (patients with granulocytic sarcoma may be included) * Previous treatment for LRD, apart from: * Hydroxyurea or previous MDS/MPN-CML therapy in AML patients * Steroids, vincristine, intrathecal prophylactic or curative injection or previous CML therapy in ALL patients * Erythroid stimulating agents (ESAs), luspatercept, granulocyte colony-stimulating factor (G-CSF), eltrombopag or other TPO agonist, iron chelation therapy, hypomethylating agents (HMAs), lenalidomide or any investigational drug previously used to treat MDS in HR-MDS patients * Hydroxyurea, standard or pegylated interferon alpha, ruxolitinib or other JAK inhibitors, busulfan, anagrelide, ESAs or any investigational drug previously used to treat MPN in MPN-related myelofibrosis patients * Patient under guardianship / curatorship * Patient under AME * Opposition of the patient to be enrolled in the eTHEMA cohort
Where this trial is running
Bobigny and 2 other locations
- Hôpital Avicenne — Bobigny, France (Recruiting)
- Hopital Robert Debré — Paris, France (Recruiting)
- Hôpital Saint Louis — Paris, France (Recruiting)
Study contacts
- Study coordinator: Hervé DOMBRET, Pr
- Email: herve.dombret@aphp.fr
- Phone: 1 57 27 68 47
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.